Predict your next investment

Private Equity
occident.group

See what CB Insights has to offer

Investments

19

Portfolio Exits

1

About Occident Group

The Occident Group is an international investment company with a goal of sustainable and meaningful asset management.

Occident Group Headquarter Location

Bahnhofstrasse 10

Zug, 6300,

Switzerland

+41 41 511 32 80

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Occident Group News

CHF 3.5M for Resistell

Dec 18, 2019

18.12.2019 13:20 Resistell, an EPFL spin-off specialising in antimicrobial treatments, has today closed an oversubscribed Series A financing round led by OCCIDENT. Multiple investors contributed to the round. The company will use the funds to obtain CE Mark for its diagnostic device. Antimicrobial resistance (AMR) is one of the biggest global health challenges today. The emergence of multi-drug resistant pathogens has made it increasingly difficult to choose the right antibiotic in time for critically ill patients. As a result, physicians are frequently turning to broad-spectrum antibiotics to reduce the risk of administering non-effective drugs. Excessive use of these powerful medicines triggers the development of multi-drug resistance. If this trend is not stopped, the world faces a death toll of up to 10 million people per year by 2050. The EPFL spin-off Resistell developed a diagnostic device that allows for identifying the best antibiotic to treat a particular infection 100 faster than conventional methods. The test is based on the measurement of vibrations of living bacteria from the sample by using nanosensors. This reduces the time-to-result from several hours or days to less than two hours and patients can be treated with the optimal medication from the first day. The need for rapid, antibiotic susceptibility tests is unquestionable. Some market analysts estimate the potential market size for these tests at CHF 4.5 billion in 2026 (Coherent Market Insights 2018). One year following the receipt of its seed funds, the startup has now raised additional CHF 3.5 million in an oversubscribed series A round led by the OCCIDENT Group. TRUMPF Venture, Alpana Ventures, Zürcher Kantonalbank, HEMEX and seven private investors also backed the start-up. The funds will enable Resistell to achieve the CE-mark declaration for the first indication, bloodstream infections. “In this round, it was very important for us to attract new institutional investors that will contribute to the strategic development of the company and support us in the long run,"  said the CEO, Danuta Cichocka. In the summer of 2019, the company together with the microbiology team led by Prof. Gilbert Greub at Lausanne University Hospital (CHUV) have also received funding for an Innosuisse Innovation project with a total budget of CHF 1.3 million. This Innosuisse grant will co-finance clinical trials at CHUV and enable validation of the technology for new indications, such as tuberculosis and chlamydia. (Press release/ran) Photo: The Resistell team: Dr Amanda Luraschi (Clinical Microbiologist), Christèle Aubry (Microbiologist, PhD student in Innosuisse project), Grzegorz Gonciarz (COO), Piotr Grygo (Engineer), Dr Grzegorz Wielgoszewski (Engineer), Dr Danuta Cichocka (Founder and CEO), Michal Swiatkowski (Engineer) and Dr Eric Delarze (Clinical Microbiologist). –

Occident Group Investments

19 Investments

Occident Group has made 19 investments. Their latest investment was in Code Intelligence as part of their Series A on June 6, 2022.

CBI Logo

Occident Group Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/1/2022

Series A

Code Intelligence

$12M

No

5

5/3/2022

Series B

Tubulis

$63M

No

2

4/26/2022

Series B

hemotune

$7.58M

No

1

8/12/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

7/21/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/1/2022

5/3/2022

4/26/2022

8/12/2020

7/21/2020

Round

Series A

Series B

Series B

Series A

Series A

Company

Code Intelligence

Tubulis

hemotune

Subscribe to see more

Subscribe to see more

Amount

$12M

$63M

$7.58M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

2

1

10

10

Occident Group Portfolio Exits

1 Portfolio Exit

Occident Group has 1 portfolio exit. Their latest portfolio exit was Cunesoft on January 09, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/9/2020

Acquired

$99M

1

Date

1/9/2020

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

1

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.